In the subgroup analysis of polyclonal antibody, the high PODXL expression was evidently related to shorter OS in cancers, using fixed-effect model (HR=1.67, 95%CI=1.40-1.99, p<0.00001; I2=48%, p=0.05), and similar result was detected in the subgroup analysis of monoclonal antibody (HR=2.13, 95%CI=1.46-3.11, p<0.0001; I2=0%, p=0.65). This evidence concerns the gene PODXL and cancer.